Top

Osteoporosis International

Published in:

Open Access 01-03-2015 | Original Article

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis

Authors: M. M. Bonafede, N. Shi, A. G. Bower, R. L. Barron, A. Grauer, D. B. Chandler

Published in: Osteoporosis International | Issue 3/2015

Abstract

Summary

The objective of this study was to describe the risk of fragility-related fractures in the 2 years following teriparatide initiation. In an administrative claims analysis of over 11,407 patients, approximately one in eight patients had a new or recurrent fragility-related fracture in the 2 years following teriparatide initiation.

Introduction

The objective of this study was to describe the risk of fragility-related fractures in the 2 years following the initiation of teriparatide in a real-world setting.

Methods

This retrospective study used data from the 2002 to 2011 MarketScan® Commercial and Medicare Supplemental Databases to identify patients 50 years and older with a diagnosis of osteoporosis (ICD-9-CM code 733.0x) who were initiating teriparatide. Patients were required to have continuous medical and pharmacy benefit coverage for the 12 months prior to and 24 months following teriparatide initiation (index event). Teriparatide treatment patterns (persistence and adherence) were described, as was the use of antiresorptive therapy. The primary study outcome was the presence of a new or recurring fragility fracture following the initiation of teriparatide.

Results

A total of 11,407 patients met the study criteria (mean age = 69.5, standard deviation = 10.6 years; 92.0 % female). One in four (25.6 %) patients had fragility fracture claims in the year prior to teriparatide initiation, of which 64.0 % were on existing antiresorptive therapy. Overall, 13.4 % (n = 1527) of patients had a new or recurrent fracture during the 2-year follow-up period. Forty-eight percent of patients on teriparatide treatment were considered persistent; fragility fractures were more common among patients nonpersistent with teriparatide (15.2 %) than among those persistent with teriparatide (11.4 %). A higher fracture rate (35.7 %) was observed in the cohort with previous fragility fracture then those without pre-index fractures (24 %).

Conclusion

More than 13.4 % of patients had new or recurrent fragility-related fractures during the 2 years following the initiation of teriparatide; these fractures were more in common in patients with pre-existing fractures and the patients who were nonpersistent with teriparatide.

Osteoporosis prevention, diagnosis, and therapy (2001) JAMA 285(6):785–795

Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513–521CrossRefPubMed

Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16(3):229–238CrossRefPubMed

Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124CrossRefPubMed

McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340CrossRefPubMed

Meijer WM, Penning-van Beest FJ, Olson M, Herings RM (2008) Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 24(11):3217–3222CrossRefPubMed

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18(8):1023–1031CrossRefPubMed

Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460CrossRefPubMed

Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90(3):1583–1587CrossRefPubMed

10.

Forteo (teriparatide injection) (2002). Product labeling. Indianapolis, IN: Eli Lilly and Company

11.

Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62(11):1515–1526CrossRef

12.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441CrossRefPubMed

13.

Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028–2039CrossRefPubMed

14.

Foster SA, Foley KA, Meadows ES et al (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 22(2):551–557CrossRefPubMed

15.

Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Nat Osteoporos Found USA 23(3):1103–1113CrossRef

16.

http://www.forteo.com/Pages/index.aspx. Accessed 30 Nov 2012

17.

Song X, Shi N, Badamgarav E et al (2011) Cost burden of second fracture in the US health system. Bone 48(4):828–836CrossRefPubMed

18.

Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23(3):585–594CrossRefPubMed

19.

Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19(10):1421–1429CrossRefPubMed

20.

Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97CrossRefPubMedCentralPubMed

21.

Foster SA, Foley KA, Meadows ES et al (2008) Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health 8:24CrossRefPubMedCentralPubMed

22.

Shi N, Foley K, Lenhart G, Badamgarav E (2009) Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45(6):1084–1090CrossRefPubMed

23.

Ziller V, Zimmermann SP, Kalder M et al (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26(3):675–681CrossRefPubMed

24.

Adachi JD, Hanley DA, Lorraine JK, Yu M (2007) Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 29(9):2055–2067CrossRefPubMed

25.

Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD (2009) Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis 1(1):5–11CrossRefPubMedCentralPubMed

26.

Gold DT, Weinstein DL, Pohl G, Krohn KD, Chen Y, Meadows ES (2011) Factors associated with persistence with teriparatide therapy: results from the DANCE observational study. J Osteoporos 2011:314970PubMedCentralPubMed

27.

Tamariz L, Uribe CL, Luo J et al (2011) Persistence with biologic therapies in the Medicare coverage gap. Am J Manag Care 17(11):753–759PubMed

28.

Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65(6):532–539CrossRefPubMed

29.

Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26(5):688–703CrossRefPubMed

Title: Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis
Authors: M. M. Bonafede
N. Shi
A. G. Bower
R. L. Barron
A. Grauer
D. B. Chandler
Publication date: 01-03-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 3/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2971-3

ACC 2024 Congress

Springer Medicine

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis

Abstract

Summary

Introduction

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Longitudinal assessment of oxytocin efficacy on bone and bone marrow fat masses in a rabbit osteoporosis model through 3.0-T magnetic resonance spectroscopy and micro-CT

Association between dietary fat intake and bone mineral density in Korean adults: data from Korea National Health and Nutrition Examination Survey IV (2008∼2009)

Bone health management in men undergoing ADT: examining enablers and barriers to care

Mediating effects on health-related quality of life in adults with osteoporosis: a structural equation modeling

Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level

Artificially low cortical bone mineral density in Turner syndrome is due to the partial volume effect